Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Luscombe, C. J.
Right arrow Articles by Strange, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Luscombe, C. J.
Right arrow Articles by Strange, R. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 22, No. 9, 1343-1347, September 2001
© 2001 Oxford University Press

ACCELERATED PAPER

Outcome in prostate cancer associations with skin type and polymorphism in pigmentation-related genes

Christopher J. Luscombe1, Michael E. French1, Samson Liu1, Mark F. Saxby1, Peter W. Jones2, Anthony A. Fryer1 and Richard C. Strange3

Department of Urology and
1 Clinical Biochemistry Research Laboratory, School of Postgraduate Medicine, North Staffordshire Hospital, Stoke-on-Trent, Staffordshire and
2 Department of Mathematics, Keele University, UK

Epidemiological studies have suggested that UV exerts a protective effect on prostate cancer. Accordingly, we determined, in 210 prostate cancer cases, whether parameters of exposure, skin type and polymorphism in MC1R, VDR and TYR were associated with the outcome parameters, histological grade, clinical stage and presence of bone metastases. We used logistic regression analysis, with correction for age and metastases, stage and grade in the models, to determine if the frequencies of individual factors were different in the patient groups. The development of metastases was not associated with UV exposure parameters. Paradoxically, patients with skin type 1 were at significantly reduced risk [P = 0.027, odds ratio (OR) 0.17, 95% CI 0.03–0.82] of developing metastases compared with cases with skin type 4. MC1R Val92/Val92 and VDR ff were associated with increased risk of metastases (ORs 4.30 and 4.98, respectively). Further, cumulative exposure (P = 0.005, OR 0.85/year) and increasing proportion of outdoor occupation (P = 0.001, OR 0.84/unit) were associated with reduced risk of advanced stage tumours. Skin types, MC1R or VDR genotypes were not significantly associated with advanced stage. None of the exposure parameters, skin types or genotypes were associated with tumour grade. While MC1R Val92/Val92 and VDR ff were only associated with bone metastases, TYR genotypes were associated with each of the outcome parameters. Thus, in logistic regression models that included age, but not advanced stage and high grade histology, TYR A1A2 was significantly associated with reduced risk of metastases (P = 0.033, OR 0.41). Similarly, in models that included age but not the other outcome parameters, associations between TYR A2A2 and high-grade and advanced stage were significant (P = 0.040, OR 0.41) or approached significance (P = 0.052, OR 0.44), respectively. These data indicate for the first time that pigmentation response to UV is associated with outcome in prostate cancer.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 AJPHHome page
C. F. Garland, F. C. Garland, E. D. Gorham, M. Lipkin, H. Newmark, S. B. Mohr, and M. F. Holick
The Role of Vitamin D in Cancer Prevention
Am J Public Health, February 1, 2006; 96(2): 252 - 261.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. K. Nam, W. W. Zhang, M. A.S. Jewett, J. Trachtenberg, L. H. Klotz, M. Emami, L. Sugar, J. Sweet, A. Toi, and S. A. Narod
The Use of Genetic Markers to Determine Risk for Prostate Cancer at Prostate Biopsy
Clin. Cancer Res., December 1, 2005; 11(23): 8391 - 8397.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
V. M. Hayes, G. Severi, E. J.D. Padilla, S. A. Eggleton, M. C. Southey, R. L. Sutherland, J. L. Hopper, and G. G. Giles
Genetic Variants in the Vitamin D Receptor Gene and Prostate Cancer Risk
Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 997 - 999.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
M. F. McCarty
Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy
Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380.
[Abstract] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. Ntais, A. Polycarpou, and J. P. A. Ioannidis
Vitamin D Receptor Gene Polymorphisms and Risk of Prostate Cancer: A Meta-analysis
Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1395 - 1402.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
Y. Xu, A. Shibata, J. E. McNeal, T. A. Stamey, D. Feldman, and D. M. Peehl
Vitamin D Receptor Start Codon Polymorphism (FokI) and Prostate Cancer Progression
Cancer Epidemiol. Biomarkers Prev., January 1, 2003; 12(1): 23 - 27.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.